The effectiveness of pregabalin with or without agomelatine in the treatment of chronic low back pain: a double-blind, placebo-controlled, randomized clinical trial

Table 2 before-after comparison of the outcome measures in patient receiving pregabalin ± placebo

Outcome of interest	Pregabalin ± Placebo (n = 23)	F	P-Value
BPI • Week 0 • Week 4 • Week 8	5.15 ± 1.96 4.39 ± 1.66 3.41 ± 1.71	46.77	< 0.001
RMDQ • Week 0 • Week 4 • Week 8	10.83 ± 5.91 8.78 ± 4.69 6.7 ± 3.32	25.72	< 0.001
SF-36 • Week 0 • Week 4 • Week 8	47.52 ± 16.94 53.52 ± 14.61 59.13 ± 11.62	34.28	< 0.001
HADS • Week 0 • Week 4 • Week 8	13.22 ± 5.7 11.48 ± 4.35 10.74 ± 4.59	52.33	0.007
GHQ-28 • Week 0 • Week 4 • Week 8	27.96 ± 10.8 25.17 ± 8.95 21.26 ± 6.62	19.14	< 0.001

BPI: Brief Pain Inventory; RMDQ: Roland-Morris Disability Questionnaire; SF-36: 36-Item Short Form Survey; HADS: Hospital Anxiety and Depression Scale; GHQ-28: General Health Questionnaire – 28
Data are presented with mean ± SD and analyzed by repeated measure ANOVA and Greenhouse-Geisser correction. A P < 0.05 is considered significant

ISSN: 2050-6511